Heres Why Brown Capital Management Small Company Fund Sold Ironwood Pharmaceuticals
IRWD Stock | USD 4.27 0.16 3.61% |
About 60% of Ironwood Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Ironwood Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Ironwood Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Ironwood Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Ironwood |
Brown Capital Management, an investment management company, released its The Brown Capital Management Small Company Fund third quarter 2024 investor letter. A copy of the letter can be downloaded here. The Small Company Fund returned 8.48 percent in the quarter, roughly in line with the Russell 2000 Growth indexs 8.41 percent return. The Fund has only gained 1.80 percent
Read at finance.yahoo.com
Ironwood Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Ironwood Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Ironwood Pharmaceuticals Fundamental Analysis
We analyze Ironwood Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ironwood Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ironwood Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Market Capitalization
Market Capitalization Comparative Analysis
Ironwood Pharmaceuticals is currently under evaluation in market capitalization category among its peers. Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Ironwood Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ironwood Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Ironwood Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Ironwood Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Ironwood Pharmaceuticals Related Equities
ASRT | Assertio Therapeutics | 4.08 | ||||
ESPR | Esperion Therapeutics | 2.33 | ||||
AMPH | Amphastar | 1.59 | ||||
COLL | Collegium Pharmaceutical | 0.14 | ||||
AVDL | Avadel Pharmaceuticals | 0.1 | ||||
ITCI | Intracellular | 0.05 | ||||
PCRX | Pacira BioSciences, | 0.00 | ||||
ANIP | ANI Pharmaceuticals | 0.02 | ||||
ALKS | Alkermes Plc | 0.07 | ||||
NBIX | Neurocrine Biosciences | 0.41 |
Complementary Tools for Ironwood Stock analysis
When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |